ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 7.4B 6.5B 6.15B 5.58B 10.48B 710B 10.54B 73.57B 28.43B 362B 27.76B 27.16B 1,164B | P/E 2026 * |
-12.7x | P/E 2027 * | -23.4x |
|---|---|---|---|---|---|
| Enterprise Value | 7.29B 6.41B 6.06B 5.5B 10.33B 700B 10.39B 72.55B 28.03B 357B 27.38B 26.78B 1,148B | EV / Sales 2026 * |
7.93x | EV / Sales 2027 * | 5.47x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 7.4B | |
| +2.64% | +7.07% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +1.71% | +50.91% | +34.00% | 44.5B | |
| -1.58% | +5.65% | +359.34% | +598.06% | 43.93B | |
| +1.70% | +4.61% | +12.56% | +90.97% | 41.03B | |
| +0.51% | -0.61% | +5.18% | +46.87% | 29.85B | |
| -0.48% | +0.59% | +23.98% | +148.36% | 17.27B | |
| +0.08% | +9.30% | +8.41% | - | 15.34B | |
| +1.76% | +2.98% | +29.13% | +45.78% | 15.3B | |
| +1.97% | -2.82% | - | - | 14.82B | |
| Average | +0.82% | +2.46% | +62.67% | +143.21% | 30B | |
| Weighted average by Cap. | +0.76% | +2.97% | +79.47% | +158.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 920M 809M 764M 694M 1.3B 88.26B 1.31B 9.15B 3.54B 45.01B 3.45B 3.38B 145B | 1.36B 1.2B 1.13B 1.03B 1.93B 131B 1.95B 13.58B 5.25B 66.8B 5.12B 5.01B 215B |
| Net income | -576M -507M -479M -435M -817M -55.31B -821M -5.73B -2.22B -28.2B -2.16B -2.12B -90.68B | -330M -290M -274M -249M -468M -31.69B -471M -3.28B -1.27B -16.16B -1.24B -1.21B -51.96B |
| Net Debt | -103M -90.58M -85.6M -77.71M -146M -9.88B -147M -1.02B -396M -5.04B -387M -378M -16.21B | 68.31M 60.08M 56.77M 51.54M 96.79M 6.56B 97.36M 680M 263M 3.34B 256M 251M 10.75B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
